Creation of an unusual designation; fresh beginnings with ex-colleagues; fundraising woes; a law suite, and more
The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.
Cadila‘s subsidiary, Zydus Cadila, received regulatory approvals to launch tetravalent inactivated influenza vaccine for seasonal flu in India. Meanwhile, Zydus received the approval from US Food and Drug Administration (FDA) for Linezolid tablets. These are used to treat skin infections and pneumonia.
Government today said it is keeping a close watch on some companies trying to create an artificial shortage of life-saving coronary stents and stringent action will taken against those engaging in unethical practices.
In a press conference in Mumbai today, the Indian Internet Pharmacy Association (IPA) called for the regulators and the government to help ensure ...
"The Drugs Controller General (India) has granted limited approval for manufacturing & marketing of stem cell based biological product Stempeucel for the treatment of Buerger's Disease," Cipla, which has investments in Stempeutics, said in a statement.
Justice Rajiv Sahai Endlaw also sought an explanation from the concerned ministry on the issue, saying they must have opted for some standard procedures before granting licences to the pharma companies.
Sources indicate that the deficiencies noted during DCGI inspections are not serious enough to attract suspension charges
With hardly any drug maker coming forth to prove safety and efficacy of 'new drugs' introduced in India without proper approval, the country's apex drug regulator has asked all such manufacturers to apply before it by August 30 or face prohibition of the drug.
Agreeing to past misdeeds, Ranbaxy Laboratories says that the company is taking measure to set things right but cliams to be unaware of DCGI probe.
Apollo'ss medical committee reviewed the matter and recommended that the pharmacy should temporarily halt sale of Ranbaxy drugs, according to a report.
In an interview to CNBC-TV18, Ganjoo says despite the company's legal saga in the US coming to an end, the company will find it difficult to see a full blown recovery.
Biotechnology major Biocon today said it has received approval from drug controller DCGI to market its product 'Itolizumab', used in the treatment of psoriasis.
India’s drug regulator DCGI has asked pharmaceutical firms to withdraw several medicines sold under the same brand name but used to treat different ailments as it leads to confusion and could harm consumers for taking a wrong medicine.